To investigate the effect of ginsenoside Rg1 on the migration, adhesion, proliferation, and VEGF expression of endothelial progenitor cells (EPCs). Methods: EPCs were isolated from human peripheral blood and incubated with different concentrations of ginsenoside Rg1 (0.1, 0.5, 1.0, and 5.0 µmol/L) and vehicle controls. EPC migration was detected with a modified Boyden chamber assay. EPC adhesion was determined by counting adherent cells on fibronectin-coated culture dishes. EPC proliferation was analyzed with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. In vitro vasculogenesis was assayed using an in vitro vasculogenesis detection kit. A VEGF-ELISA kit was used to measure the amount of VEGF protein in the cell culture medium. Results: Ginsenoside Rg1 promoted EPC adhesion, proliferation, migration and in vitro vasculogenesis in a dose-and timedependent manner. Cell cycle analysis showed that 5.0 µmol/L of ginsenoside Rg1 significantly increased the EPC proliferative phase (S phase) and decreased the resting phase (G 0 /G 1 phase). Ginsenoside Rg1 increased vascular endothelial growth factor production.
Introduction
Endothelial progenitor cells (EPCs) have the ability to circulate, proliferate and differentiate into mature endothelial cells, but have not yet acquired characteristic mature endothelial cell markers or formed a lumen [1] . Reduced numbers of EPCs reflect an impaired endogenous repair capacity and predict future cardiovascular events [2] [3] . Therefore, stimulation of mobilization and differentiation of EPCs may provide a novel therapeutic strategy for improvement of postnatal neovascularization and re-endothelialization in coronary heart disease (CHD) patients. Ricousse-Roussanne et al [4] demonstrated that progenitors of both endothelial cells and smooth muscle cells were present in cord blood and could differentiate into mature endothelial and smooth muscle cells. In terms of cardiovascular diseases, the increase in the number of EPCs could be a potential benefit. Ginseng, the root of Panax ginseng CA Meyer, has been used for thousands of years in traditional Chinese medicine. Its name is derived from the Greek pan (all) and akos (healing) [5] . With the development of modern technology, more and more active ingredients have been isolated and purified from the herb. Ginsenoside Rg1 is panaxtriol with two sugars. The activity of ginseng extract has been studied extensively. Ginsenoside Rg1 is an active ingredient commonly found in ginseng root. Of more than 30 different ginsenosides, ginsenoside Rg1 is among the most abundant and active ingredients [6] . Ginsenoside Rg1, a stable angiogenic agent, successfully enhanced myocardial perfusion and preserved infarcted left ventricle function [7] . Following treatment with ginsenoside Rg1, the number of CD34 + cells increased significantly in peripheral blood, and the ability of bone marrow stem cells to repair infracted myocardium increased in rats with ischemic myocardia. Ginsenoside Rg1 was demonstrated to be a phytoestrogen that exerted estrogen-like activity without direct interaction with estrogen receptors in human breast cancer (MCF-7) cells [8] . Estrogen therapy was found to have a similar impact on the number of circulating EPCs [9] . Administration of estrogen could result in increased numbers of EPCs by anti-apoptotic effects [9] . Ginsenoside Rg1 exerts estrogen-like actions via ligand-independent activation of the ERalpha pathway [10] . In the present study, we aim to investigate the direct modulatory effect of ginsenoside Rg1 on the function of EPCs in vitro. We demonstrated that ginsenoside Rg1 promoted EPC proliferation, adhesion and angiogenesis. The results provide further insight into the possible therapeutic use of ginsenoside Rg1 for re-endothelialization and induction of angiogenesis, such as in atherosclerosis, restenosis and tissue regeneration.
Materials and methods

Isolation of mononuclear cells and cell culture
EPCs were cultured according to a previously described technique [11, 12] . Briefly, peripheral blood mononuclear cells (MNCs) were isolated from healthy volunteers by Ficoll density gradient centrifugation with Histopaque 1077 (Sigma, St Louis, MO, USA). Written informed consent was obtained from all volunteers involved in the study. None of the volunteers had risk factors for coronary heart disease, and they were free of wounds, inflammation, ulcers and malignant disease. All the procedures were performed in accordance with national and international laws and policies. Cells were plated on 6-well culture plates coated with human fibronectin (2 µg/cm 2 ; Millipore Corporation, USA & Canada) and maintained in Medium 199 (M199; Sigma, USA) supplemented with 20% fetal bovine serum (FBS; GIBCO16000, USA), vascular endothelial growth factor (VEGF; 10 µg/L; Peprotech Inc, USA), bovine brain extract (12 µg/mL; Sigma, USA), penicillin (100 U/mL), and streptomycin (100 µg/mL). After 4 days of culture, non-adherent cells were removed by washing with phosphate-buffered saline (PBS). New medium was added and the cells were cultivated for 3 days. Before experiments, cells had been deprived of serum for 24 h. o C for 1 h and later fixed with 2% paraformaldehyde for 10 min. After being washed, the cells were treated with UEA-1 (10 µg/mL) for 1 h. Following staining, samples were then viewed with an inverted fluorescent microscope (Leica, Germany) and a laser scanning confocal microscope (LSCM; Leica, Germany). Cells that were doubly fluorescent were identified as differentiating EPC [13] [14] [15] . Two or three independent investigators evaluated the number of EPCs per well by counting 15 randomly selected high-power fields (×200) with an inverted fluorescent microscope. The cells were further analyzed by immunostaining with goat polyclonal anti-CD31 antibody (Santa Cruz Biotechnology, USA) and goat polyclonal antivon Willebrand factor antibodies (vWF; Sigma, USA). The cells were plated on 6-well chamber slides for 7 d, then washed and fixed with acetone at 4 °C for 10 min. The cells were blocked with 5% horse serum for 30 min and incubated overnight at 4 °C in 1:100 dilutions of goat polyclonal antivWF and CD31 antibodies, followed by incubation with horseradish peroxidase-conjugated anti-goat IgG for an additional 30 min. The slides were visualized with DAB-based color development.
Migration assay EPC migration was evaluated using a modified Boyden chamber assay. Briefly, isolated EPCs were detached using 1 mmol/L EDTA in PBS, harvested by centrifugation at 400×g for 10 min at room temperature, resuspended in 500 µL M199 and counted. Then, 5×10 4 EPCs were placed in the upper chamber of a modified Boyden chamber ( Jiangsu Qilin Medical Equipment Factory, China). M199 and human recombinant VEGF (50 ng/mL) were placed in the lower compartment of the chamber. After a 24 h incubation at 37 o C, the lower side of the filter was washed with PBS and fixed with 2% paraformaldehyde. For quantification, cells were stained with Giemsa solution. Cells migrating into the lower chamber were counted manually in three random microscopic fields (×200) [14, 15] . Cell adhesion assay EPCs were washed with PBS and gently detached with 0.25% trypsin. After centrifugation at 225×g for 10 min at room temperature and resuspension in M199 with 5% FBS, identical cell numbers were replated onto fibronectin-coated culture dishes and incubated for 30 min at 37 o C. Adherent cells were counted manually in five random microscopic fields (×200) by independent blinded investigators [16] . EPC proliferation assay The effect of ginsenoside Rg1 on EPC proliferation was determined by 3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. EPCs cultured for 7 d were digested with 0.25% trypsin and then cultured in serum-free medium in 96-well culture plates (200 µL per well) to which different concentrations of ginsenoside Rg1 were added (n=6 wells/concentration). The serum-free medium served as a vehicle control. After being cultured for 24 h, EPCs were supplemented with 10 µL MTT (5 g/L; Ameresco, Framingham, MA, USA) and incubated for another 4 h. Then, the supernatant was discarded by aspiration, and the EPC preparation was shaken with 200 µL DMSO for 10 min, before the optical density (OD) value was measured at 490 nm.
In vitro vasculogenesis assay The in vitro vasculogenesis assay was performed with the in vitro Angiogenesis Assay Kit (Chemicon International, USA & Canada), according to the manufacturer's instructions. Briefly, ECMatrix Tubule formation was defined as development of a structure with a length at least 4 times its width [17, 18] . Five independent fields were assessed for each well, and the average number of tubules per 200×field was determined.
Cell cycle analysis EPCs were treated with ginsenoside Rg1 for 24 h, and cells were isolated into conical tubes, washed twice with PBS and fixed in 75% ice-cold ethanol. For DNA analysis, cells were centrifuged at 400×g for 10 min at room temperature and washed twice with PBS. After incubation at 37 o C in the dark for 30 min, the DNA content of the nuclei was determined by staining nuclear DNA with propidium iodide solution (50 µg/mL, sigma, USA) containing 50 µg/mL ribonuclease A. The DNA content was measured by a flow cytometer (Becton Dickinson, USA).
Measurement of VEGF protein in the culture medium To assess secretion of the vascular endothelial growth factor (VEGF) protein, EPCs (1×10 6 ) treated with or without ginsenoside Rg1 were switched at d 14 to growth factorfree medium M199 with 5% FBS for 24 h. VEGF protein in the cell culture medium was measured using a commercially available VEGF-Elisa kit (R&D systems, Minneapolis, MN, USA), according to the manufacturer′s instructions. The assay system has no cross-reactivity with platelet-derived growth factor and basic fibroblast growth factor.
Statistical analysis Data analysis was performed using the Statistical Package for Social Science (SPSS for Windows, version 10.0, 1999, SPSS Inc, Chicago, USA). Data are expressed as mean±SD. We used one-way ANOVA and the independent-samples t-test to analyze the differences in variables. The differences were considered significant if P<0.05.
Results
Characteristics of human EPC Mononuclear cells isolated from peripheral blood were immediately plated onto culture plates pre-coated with human fibronectin. They appeared small and round under an inverted light microscope ( Figure 1A ). After 7 days in culture, attached cells exhibited a spindle-shape, with an endothelial cell-like morphology ( Figure 1B) . The cells tested for DiI-labeled acetylated lowdensity lipoprotein (DiLDL) uptake, lectin binding and double labeling were stained. Double labeling cells represented about 80% of the culture cells. EPCs were characterized as adherent cells that were double-positive for DiLDL-uptake and lectin binding under a laser scanning confocal microscope ( Figure 1C-1D) . Immunohistochemistry showed that the cells were positive for endothelial cell surface marker antibodies, such as vWF and CD31 ( Figure 1E-1F) .
Effect of ginsenoside Rg1 on EPC proliferation The MTT assay was used to demonstrate the effect of ginsenoside Rg1 on EPC proliferation. Incubation of isolated human MNCs with ginsenoside Rg1 increased EPC proliferative capacity in a concentration-and time-dependent manner ( Figure 2) . In dose-dependent experiments, the EPC proliferative activity was greatest at 5.0 µmol/L ginsenoside Rg1 [0.27±0.09 vs 0.58±0.08 (light absorbance at 490 nm) for vehicle control and 5.0 µmol/L ginsenoside Rg1, respectively; P<0.01; Figure 2A ]. In time-course experiments with EPCs treated with 5.0 µmol/L ginsenoside Rg1, increases in EPC proliferation became apparent after 12 h (P<0.01) and reached the maximum at 24 h (P<0.01; Figure 2B) .
Effect of ginsenoside Rg1 on EPC adhesiveness EPCs were incubated with different concentrations (0, 0.1, 0.5, 1.0, and 5.0 µmol/L) of ginsenoside Rg1 for 24 h. EPCs were then placed on fibronectin-coated dishes for 30 min.
EPCs pretreated with ginsenoside Rg1 exhibited a significant increase in the number of adhesive cells after 30 min. The change in the number of adhesive cells was dose-dependent with the maximal effect at 5.0 µmol/L ginsenoside Rg1. In the time-course study, the increase in EPC adhesive activity became apparent at 6 h and reached its maximum at 24 h (Figure 3) .
Effect of ginsenoside Rg1 on EPC migration EPCs were incubated with different concentrations of ginsenoside Rg1, and effects on EPC migratory activity were analyzed in a modified Boyden chamber assay. In dose-response experiments, ginsenoside Rg1 enhanced cell migration, and this effect was greatest at 5.0 µmol/L ginsenoside Rg1 (13.80±2.77 vs 25.20±6.14 for vehicle control and ginsenoside Rg1 5.0 µmol/L , respectively; P<0.05; Figure 4A ). When EPCs were treated with 5.0 µmol/L ginsenoside Rg1, migratory activity was enhanced after 6 h (P<0.05) and reached a maximum at 24 h (P<0.01; Figure 4 
B).
Effect of ginsenoside Rg1 on EPC vasculogenesis in vitro An in vitro vasculogenesis assay kit was used to investigate the ability of EPCs to undergo neovascularization following ginsenoside Rg1 treatment. Tubule number increased in a concentration-dependent manner in response to Rg1 after 24 h of incubation ( Figure 5 ). The peak tubule number resulted following treatment with 5.0 µmol/L ginsenoside Rg1, and the tubules were more complex than that in control cells.
Effect of ginsenoside Rg1 on cell cycle Effects of ginsenoside Rg1 on the cell cycle in EPCs were determined by flow cytometry. Ginsenoside Rg1 induced a significant increase in the proliferative phase (S phase) and decrease in the resting phase (G 0 /G 1 ) of the cell cycle ( Figure 6 ).
Effect of ginsenoside Rg1 on VEGF secretion
In the study, we evaluated the secretion of vascular endothelial growth factor (VEGF) by EPCs. The concentration of VEGF in the culture medium was greater following ginsenoside Rg1 treatment of EPCs when compared to untreated controls ( Figure 7 ).
Discussion
Endothelial progenitor cells (EPCs) play an important role in the regeneration of ischemic and damaged tissues via angiogenesis and repairing denuded endothelium in injured vessels [13, 19, 20] . It has been noted that EPCs contributed up to 25% of the endothelial cells in newly formed vessels [21, 22] . There is an inverse relationship between EPC number and family history of coronary artery disease [23] , age [24] , diabetes [23] , smoking [25] , and hypertension [26] . The number of EPCs is higher in subjects with low to moderate alcohol consumption . The mechanisms responsible for the increase in the number and activity of EPCs are not very clear. Standard cardiovascular drugs, such as statins and ACE inhibitor/angiotensin-receptor blockers, are capable of enhancing the number of EPCs [27] [28] [29] . Vascular endothelial growth factor (VEGF) is probably the most important angiogenesis inducer. It has the ability to regulate key steps in angiogenesis, including proliferation and migration of endothelial cells [30] . Over-expression of VEGF and its receptors promotes blood vessel formation, and VEGF inhibition blocks angiogenesis [31] . Leung KW et al showed that ginsenoside Rg1 promoted the synthesis of VEGF and hence angiogenic activity by activating the PI3K/Akt pathway [32] . Ginsenoside Rg1 could enhance nitric oxide production and the expression of eNOS mRNA in TNF-alpha stimulated HUVECs [33] . Ginsenoside Rg1 could mobilize more bone marrow stem cells to infarcted zones to differentiate to cardiomyocyte-like cells [34] . Accumulating evidence indicates the ability of blood EPCs to repair injured vessels of dying endothelial cells in animal models [35] . Thus, increasing the number of circulating EPCs by transplantation of hematopoietic stem cells or by injection of differentiated EPCs in vitro has been shown to improve neovascularization of ischemic hindlimbs [36] and cardiac function [37] . There are two major classes of ginsenosides: protopanaxatriols (Rg1, Rg2, Re, and Rf) and protopanaxadiols (Rb1, Rb2, Rc, and Rd). They both possess four trans-ring rigid steroid skeletons with a modified side-chain at C20, which is absent in estradiol [8] . Re and Rg1 may be a novel group of non-peptidic angiogenic agents with superior stability and may be used for the management of tissue regeneration [38] . BMSC proliferation stimulated by ginsenoside Rg1 can be completely blocked by ER antagonist ICI 182, 780, or ERα-specific antagonist methylpiperidinopyrazole, which indicates that ERα may be the key subunit that enables Rg1 to exert its action on BMSC [39] . Rg1 did not directly bind to ER or change the expression of ERα in BMSC, which was confirmed by RT-PCR and Western blotting [39] . In this study, EPCs derived from human peripheral blood could differentiate into cells that display classical endothelial cell morphology and characteristics, such as the capacity to take up acetylated low-density lipoprotein and the expression of vWF and CD31. The present study shows that ginsenoside Rg1 could increase the number of EPCs and promote the proliferative, migratory and adhesive capacity of EPCs. The in vitro vasculogenesis capacity of EPCs was effectively elevated. Cell cycle analysis illustrated that the effect of ginsenoside Rg1 was achieved by stimulation of the G 1 /S transition in EPCs. Moreover, ginsenoside Rg1 increased EPC production of VEGF in a concentration-dependent manner. Ginsenoside Rg1 has been reported to trigger transcriptional activation of the glucocorticoid-responsive elementcontaining reporter gene, suggesting that ginsenoside Rg1 could activate the glucocorticoid receptor-2 [40] [41] [42] . In prior work, ginsenoside Rg1 has been demonstrated to promote functional neovascularization into a polymer scaffold in vivo, as well as the proliferation, chemoinvasion, and tubulogenesis of endothelial cell in vitro [43] . These data indicate that ginsenoside Rg1 can be used as a novel therapeutic modality for inducing angiogenesis.
In conclusion, ginsenoside Rg1 has direct effects on human EPCs in vitro. The results of the present study demonstrated that ginsenoside Rg1 promoted EPC proliferation, adhesion, migration and vasculogenesis. The levels of secreted VEGF were elevated after ginsenoside Rg1 treatment of EPCs, although the evidence did not indicate that all the effects of ginsenoside Rg1 on EPCs were because of VEGF. Further studies will determine whether the ginsenoside Rg1-induced EPC effects could be eliminated by removing the effect of VEGF. The findings provide important insight into the molecular and cellular mechanisms mediated by ginsenoside Rg1 in endothelial repair and protection against myocardial ischemia. 
